Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use DASATINIB TABLETS safely and effectively. See full prescribing information for DASATINIB TABLETS DASATINIB tablets, for oral use Initial U.S. Approval: 2006
Medication labelWhy this: Advisory · dailymed-prescription
Dasatinib tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablet is indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. Additional pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
- generic_name
- dasatinib
- product_names
- DASATINIB
- ndc
- 46708-684, 46708-685, 46708-686, 46708-687, 46708-688, 46708-689, 46708-684-60, 46708-685-60, 46708-686-60, 46708-687-30, 46708-688-30, 46708-689-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en